INQ000479901 – Report from Rapid C-19 Oversight Group, titled tixagevimab and cilgavimab (Evusheld, AZD7442; AstraZeneca) in pre-exposure prophylaxis, dated 24/08/2022.

Report from Rapid C-19 Oversight Group, titled tixagevimab and cilgavimab (Evusheld, AZD7442; AstraZeneca) in pre-exposure prophylaxis, dated 24/08/2022.

Modiwl 4 a godwyd:
• Tudalennau 1, 6-8, 10-12 ac 16 ar 30 Ionawr 2025

Gwneud lawrlwytho'r ddogfen hon

• Saesneg (PDF)